Is Buying Stock Like Cytokinetics, Inc. (CYTK) After Such Increase Winning Strategy?

September 17, 2017 - By Winifred Garcia

Investors sentiment decreased to 1.08 in 2016 Q4. Its down 0.08, from 1.16 in 2016Q3. It dropped, as 8 investors sold Cytokinetics, Inc. shares while 30 reduced holdings. 17 funds opened positions while 24 raised stakes. 26.15 million shares or 1.34% less from 26.51 million shares in 2016Q3 were reported.
Moreover, Morgan Stanley has 0% invested in Cytokinetics, Inc. (NASDAQ:CYTK). Palo Alto Invsts Lc has invested 0.09% in Cytokinetics, Inc. (NASDAQ:CYTK). Federated Inc Pa stated it has 0% in Cytokinetics, Inc. (NASDAQ:CYTK). 163,260 are held by United Svcs Automobile Association. Globeflex L P reported 139,065 shares stake. Airain Ltd reported 21,800 shares. Sg Americas Securities Limited Liability Co holds 15,551 shares or 0% of its portfolio. Fmr Limited Company reported 5.20M shares or 0.01% of all its holdings. Wellington Mgmt Group Limited Liability Partnership has invested 0% of its portfolio in Cytokinetics, Inc. (NASDAQ:CYTK). Bnp Paribas Arbitrage Sa holds 0% of its portfolio in Cytokinetics, Inc. (NASDAQ:CYTK) for 1,905 shares. Deutsche Bank & Trust Ag reported 0% stake. Commercial Bank Of Mellon owns 164,479 shares or 0% of their US portfolio. Royal Bankshares Of Canada invested in 2,137 shares or 0% of the stock. Rhumbline Advisers reported 0% in Cytokinetics, Inc. (NASDAQ:CYTK). 71,491 were reported by Goldman Sachs Group.

Since June 1, 2017, it had 0 buys, and 1 sale for $68,093 activity.

The stock of Cytokinetics, Inc. (NASDAQ:CYTK) is a huge mover today! The stock increased 3.66% or $0.5 on September 15, reaching $14.15. About 946,182 shares traded or 94.34% up from the average. Cytokinetics, Inc. (NASDAQ:CYTK) has risen 88.33% since September 17, 2016 and is uptrending. It has outperformed by 71.63% the S&P500.
The move comes after 8 months positive chart setup for the $732.55M company. It was reported on Sep, 17 by Barchart.com. We have $14.86 PT which if reached, will make NASDAQ:CYTK worth $36.63M more.

Analysts await Cytokinetics, Inc. (NASDAQ:CYTK) to report earnings on October, 26. They expect $-0.61 earnings per share, down 182.43 % or $1.35 from last year’s $0.74 per share. After $-0.60 actual earnings per share reported by Cytokinetics, Inc. for the previous quarter, Wall Street now forecasts 1.67 % negative EPS growth.

Cytokinetics, Inc. (NASDAQ:CYTK) Ratings Coverage

Among 9 analysts covering Cytokinetics (NASDAQ:CYTK), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cytokinetics had 10 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, August 3 by H.C. Wainwright. As per Wednesday, July 27, the company rating was maintained by Needham. On Monday, November 9 the stock rating was maintained by TH Capital with “Buy”. The rating was maintained by JMP Securities with “Market Outperform” on Wednesday, March 9. The company was maintained on Tuesday, November 10 by FBR Capital. As per Monday, November 9, the company rating was maintained by Roth Capital. As per Monday, February 6, the company rating was upgraded by Needham. On Friday, December 16 the stock rating was initiated by Cantor Fitzgerald with “Overweight”. On Friday, July 24 the stock rating was maintained by MLV with “Buy”. As per Thursday, August 3, the company rating was maintained by Cowen & Co.

More notable recent Cytokinetics, Inc. (NASDAQ:CYTK) news were published by: Globenewswire.com which released: “Cytokinetics, Inc. Reports First Quarter 2017 Financial Results” on April 27, 2017, also Globenewswire.com with their article: “Cytokinetics to Present at September Investor Conferences” published on September 05, 2017, Seekingalpha.com published: “Cytokinetics’ (CYTK) CEO Robert Blum on Q4 2016 Results – Earnings Call Transcript” on February 17, 2017. More interesting news about Cytokinetics, Inc. (NASDAQ:CYTK) were released by: Globenewswire.com and their article: “Cytokinetics Added to S&P SmallCap 600” published on April 21, 2017 as well as Nasdaq.com‘s news article titled: “Cytokinetics, Inc. Reports Second Quarter 2017 Financial Results” with publication date: August 02, 2017.

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The company has market cap of $732.55 million. The Firm is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It currently has negative earnings. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.